Further, m6A/METTL3 modulates ferroptosis-associated cancer progression through the regulation of SLC7A11 transcription, as illustrated in Fig. 8L. This suggests that activation of METTL3 may be a potential approach to increase the sensitivity of ferroptosis-based therapy for cancer treatment. This evidence concerns the gene METTL3 and cancer.